Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400165 | 1.00 | LMNA (0.50) | LMNAHRH4MAPTCYP1A2CYP2D6 | |
| SCHEMBL1320304 | 0.86 | LMNA (0.41) | LMNAHRH4MAPTCYP1A2CYP2D6 | |
| SCHEMBL3205249 | 0.79 | HRH4 (0.39) | HRH4 | |
| SCHEMBL15654940 | 0.79 | SYK (0.39) | — | |
| SCHEMBL5076739 | 0.78 | LMNA (0.56) | LMNAHRH4MAPTCYP1A2CYP2D6 | |
| SCHEMBL1775506 | 0.78 | LMNA (0.56) | LMNAHRH4MAPTCYP1A2CYP2D6 | |
| SCHEMBL6023882 | 0.78 | LMNA (0.56) | LMNAHRH4MAPTCYP1A2CYP2D6 | |
| SCHEMBL5076737 | 0.77 | LMNA (0.55) | LMNAHRH4MAPTCYP1A2CYP2D6 | |
| SCHEMBL6023878 | 0.77 | LMNA (0.55) | LMNAHRH4MAPTCYP1A2CYP2D6 | |
| SCHEMBL1775505 | 0.77 | LMNA (0.55) | LMNAHRH4MAPTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | LMNA 4860/4885HRH4 1/4885MAPT 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.